177 related articles for article (PubMed ID: 36219398)
21. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.
Bunt J; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
PLoS One; 2011; 6(10):e26058. PubMed ID: 22016811
[TBL] [Abstract][Full Text] [Related]
22. HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.
Xue Y; Lian W; Zhi J; Yang W; Li Q; Guo X; Gao J; Qu H; Lin W; Li Z; Lai L; Wang Q
Br J Cancer; 2019 Dec; 121(12):1039-1049. PubMed ID: 31690832
[TBL] [Abstract][Full Text] [Related]
23. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
24. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
25. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.
Suryo Rahmanto A; Savov V; Brunner A; Bolin S; Weishaupt H; Malyukova A; Rosén G; Čančer M; Hutter S; Sundström A; Kawauchi D; Jones DT; Spruck C; Taylor MD; Cho YJ; Pfister SM; Kool M; Korshunov A; Swartling FJ; Sangfelt O
EMBO J; 2016 Oct; 35(20):2192-2212. PubMed ID: 27625374
[TBL] [Abstract][Full Text] [Related]
26. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
[TBL] [Abstract][Full Text] [Related]
27. Tumor cells generate astrocyte-like cells that contribute to SHH-driven medulloblastoma relapse.
Guo D; Wang Y; Cheng Y; Liao S; Hu J; Du F; Xu G; Liu Y; Cai KQ; Cheung M; Wainwright BJ; Lu QR; Zhao Y; Yang ZJ
J Exp Med; 2021 Sep; 218(9):. PubMed ID: 34254999
[TBL] [Abstract][Full Text] [Related]
28. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
29. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
[TBL] [Abstract][Full Text] [Related]
30. SOX9 Defines Distinct Populations of Cells in SHH Medulloblastoma but Is Not Required for Math1-Driven Tumor Formation.
Adolphe C; Millar A; Kojic M; Barkauskas DS; Sundström A; Swartling FJ; Hediyeh-Zadeh S; Tan CW; Davis MJ; Genovesi LA; Wainwright BJ
Mol Cancer Res; 2021 Nov; 19(11):1831-1839. PubMed ID: 34330843
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
Qin N; Paisana E; Langini M; Picard D; Malzkorn B; Custódia C; Cascão R; Meyer FD; Blümel L; Göbbels S; Taban K; Bartl J; Bechmann N; Conrad C; Gravemeyer J; Becker JC; Stefanski A; Puget S; Barata JT; Stühler K; Fischer U; Felsberg J; Ayrault O; Reifenberger G; Borkhardt A; Eisenhofer G; Faria CC; Remke M
Neuro Oncol; 2022 Sep; 24(9):1509-1523. PubMed ID: 35307743
[TBL] [Abstract][Full Text] [Related]
32. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.
Li Y; Guessous F; Johnson EB; Eberhart CG; Li XN; Shu Q; Fan S; Lal B; Laterra J; Schiff D; Abounader R
Lab Invest; 2008 Feb; 88(2):98-111. PubMed ID: 18059365
[TBL] [Abstract][Full Text] [Related]
33. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
34. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
35. Myc proteins in brain tumor development and maintenance.
Swartling FJ
Ups J Med Sci; 2012 May; 117(2):122-31. PubMed ID: 22348395
[TBL] [Abstract][Full Text] [Related]
36. Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells.
Colvin Wanshura LE; Galvin KE; Ye H; Fernandez-Zapico ME; Wetmore C
Cancer Res; 2011 Aug; 71(15):5336-45. PubMed ID: 21646478
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
Rutkowski S; von Bueren A; von Hoff K; Hartmann W; Shalaby T; Deinlein F; Warmuth-Metz M; Soerensen N; Emser A; Bode U; Mittler U; Urban C; Benesch M; Kortmann RD; Schlegel PG; Kuehl J; Pietsch T; Grotzer M
Clin Cancer Res; 2007 May; 13(9):2651-7. PubMed ID: 17473196
[TBL] [Abstract][Full Text] [Related]
38. The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.
Thompson EM; Whitney NL; Wu YJ; Neuwelt EA
J Neurosurg Pediatr; 2013 Jan; 11(1):60-7. PubMed ID: 23082872
[TBL] [Abstract][Full Text] [Related]
39. Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition.
Graziani V; Garcia AR; Alcolado LS; Le Guennec A; Henriksson MA; Conte MR
Sci Rep; 2023 Jan; 13(1):1273. PubMed ID: 36690651
[TBL] [Abstract][Full Text] [Related]
40. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
